At a glance
- Originator Bristol-Myers Squibb
- Class Antibacterials; Oxazolidinones; Small molecules
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anaerobic infections; Gram-positive infections
Most Recent Events
- 18 Sep 2001 Discontinued-I for Anaerobic infections in USA (Unknown route)
- 18 Sep 2001 Discontinued-I for Gram-positive infections in USA (Unknown route)